Emsam Deal Marks Bristol's Return To The Antidepressant Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Under an agreement with the Mylan/Watson joint venture Somerset, Bristol will handle all marketing and detailing of the selegiline transdermal patch, which has been "approvable" at FDA since February 2004. Bristol left the antidepressant category in June when it stopped selling Serzone.
You may also be interested in...
Emsam Antidepressant Patch Approved; April Launch Anticipated
Bristol/Somerset’s product avoids MAOI-class dietary restrictions at the lowest dose.
Emsam Antidepressant Patch Approved; April Launch Anticipated
Bristol/Somerset’s product avoids MAOI-class dietary restrictions at the lowest dose.
Somerset Emsam Gets Committee Review To Evaluate Dietary Restrictions
FDA's Psychopharmacologic Drugs Advisory Committee to meet Oct. 25-26; the panel will also discuss need for longer-term efficacy data for chronic psychiatric therapies.